 Todd Kingdom
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 25 | 2021 | 221 | 3.730 |
Why?
| | Rhinitis | 23 | 2023 | 158 | 3.470 |
Why?
| | Nasal Polyps | 15 | 2017 | 59 | 3.060 |
Why?
| | Endoscopy | 21 | 2024 | 318 | 2.710 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 80 | 1.910 |
Why?
| | Paranasal Sinus Neoplasms | 7 | 2024 | 28 | 1.380 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 10 | 1.070 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 101 | 0.980 |
Why?
| | Nasal Mucosa | 6 | 2019 | 107 | 0.970 |
Why?
| | Skull Base | 6 | 2023 | 53 | 0.900 |
Why?
| | Aspirin | 6 | 2016 | 387 | 0.860 |
Why?
| | Cystic Fibrosis | 7 | 2014 | 1114 | 0.750 |
Why?
| | Orbit | 4 | 2016 | 70 | 0.690 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 350 | 0.590 |
Why?
| | Postoperative Complications | 7 | 2018 | 2654 | 0.570 |
Why?
| | Lipoxygenase | 2 | 2008 | 18 | 0.550 |
Why?
| | Chronic Disease | 19 | 2023 | 1793 | 0.550 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 11 | 0.530 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 3 | 0.490 |
Why?
| | Decompression, Surgical | 2 | 2017 | 106 | 0.470 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 10 | 0.470 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 15 | 0.440 |
Why?
| | Protein Array Analysis | 2 | 2011 | 57 | 0.390 |
Why?
| | Eosinophilia | 3 | 2016 | 218 | 0.380 |
Why?
| | Bronchiectasis | 1 | 2013 | 111 | 0.370 |
Why?
| | Respiratory System | 1 | 2013 | 157 | 0.370 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 26 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 233 | 0.360 |
Why?
| | Sputum | 1 | 2013 | 311 | 0.360 |
Why?
| | Middle Aged | 33 | 2024 | 33479 | 0.360 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 40 | 0.350 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 43 | 0.350 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 132 | 0.350 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2691 | 0.340 |
Why?
| | Immunotherapy | 1 | 2015 | 641 | 0.340 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 740 | 0.330 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 27 | 0.330 |
Why?
| | Humans | 71 | 2024 | 137585 | 0.330 |
Why?
| | Frontal Sinus | 2 | 2007 | 5 | 0.330 |
Why?
| | Surgical Flaps | 3 | 2019 | 130 | 0.320 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 10 | 0.320 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 28 | 0.310 |
Why?
| | Adult | 32 | 2024 | 37929 | 0.310 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 178 | 0.310 |
Why?
| | Mycoses | 3 | 2005 | 79 | 0.300 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.290 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 8 | 0.290 |
Why?
| | Retrospective Studies | 22 | 2022 | 15657 | 0.290 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 77 | 0.290 |
Why?
| | Male | 40 | 2024 | 67762 | 0.280 |
Why?
| | Treatment Outcome | 14 | 2024 | 10811 | 0.270 |
Why?
| | Aged | 24 | 2024 | 23961 | 0.270 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 606 | 0.270 |
Why?
| | Immunoglobulin E | 2 | 2018 | 342 | 0.270 |
Why?
| | Female | 37 | 2024 | 73304 | 0.250 |
Why?
| | Quality of Life | 5 | 2024 | 2892 | 0.250 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 87 | 0.250 |
Why?
| | Nose Neoplasms | 2 | 1996 | 25 | 0.250 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1587 | 0.240 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 18 | 0.230 |
Why?
| | Consensus | 3 | 2021 | 683 | 0.230 |
Why?
| | Osteomyelitis | 1 | 2007 | 132 | 0.230 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 119 | 0.220 |
Why?
| | Hypersensitivity | 3 | 2024 | 257 | 0.220 |
Why?
| | Streptococcus | 1 | 2004 | 28 | 0.220 |
Why?
| | Prednisone | 2 | 2017 | 240 | 0.220 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 73 | 0.220 |
Why?
| | Staphylococcus | 1 | 2004 | 76 | 0.220 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 40 | 0.210 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 16 | 0.210 |
Why?
| | Adenoma | 2 | 2018 | 230 | 0.200 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 30 | 0.200 |
Why?
| | Bone Diseases | 1 | 2003 | 62 | 0.200 |
Why?
| | Aged, 80 and over | 11 | 2024 | 7635 | 0.200 |
Why?
| | Reoperation | 3 | 2019 | 573 | 0.180 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 352 | 0.180 |
Why?
| | Adolescent | 14 | 2019 | 21513 | 0.180 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 31 | 0.180 |
Why?
| | Glucocorticoids | 2 | 2017 | 594 | 0.170 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 7 | 0.170 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 8 | 0.170 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1483 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Nasal Septum | 2 | 2020 | 25 | 0.150 |
Why?
| | Sella Turcica | 1 | 2018 | 18 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 14 | 0.150 |
Why?
| | Otolaryngology | 2 | 2011 | 96 | 0.150 |
Why?
| | Up-Regulation | 2 | 2012 | 843 | 0.150 |
Why?
| | Parotid Diseases | 1 | 1998 | 5 | 0.150 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 10 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 11 | 0.150 |
Why?
| | Sclerotherapy | 1 | 1998 | 20 | 0.150 |
Why?
| | Doxycycline | 1 | 1998 | 62 | 0.140 |
Why?
| | Vision Disorders | 2 | 2017 | 142 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1738 | 0.140 |
Why?
| | Prospective Studies | 5 | 2024 | 7604 | 0.140 |
Why?
| | Immunoglobulin D | 1 | 2017 | 30 | 0.140 |
Why?
| | Mucocele | 1 | 2017 | 12 | 0.140 |
Why?
| | Cysts | 1 | 1998 | 113 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 143 | 0.140 |
Why?
| | Melanoma | 2 | 1995 | 760 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2015 | 5131 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 190 | 0.130 |
Why?
| | Aspergillosis | 1 | 1996 | 21 | 0.130 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 26 | 0.130 |
Why?
| | Visual Acuity | 2 | 2017 | 356 | 0.130 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 23 | 0.120 |
Why?
| | Neuroendoscopy | 1 | 2016 | 23 | 0.120 |
Why?
| | Graves Disease | 1 | 2016 | 34 | 0.120 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 77 | 0.120 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 8 | 0.120 |
Why?
| | Superantigens | 1 | 2015 | 70 | 0.120 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 127 | 0.120 |
Why?
| | Pharynx | 1 | 1995 | 59 | 0.120 |
Why?
| | Mouth | 1 | 1995 | 87 | 0.120 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 531 | 0.120 |
Why?
| | Neck | 3 | 2005 | 101 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 76 | 0.120 |
Why?
| | Dinoprostone | 1 | 2015 | 191 | 0.110 |
Why?
| | Nasal Cavity | 1 | 1995 | 52 | 0.110 |
Why?
| | Young Adult | 8 | 2018 | 13209 | 0.110 |
Why?
| | Meningitis | 1 | 2016 | 79 | 0.110 |
Why?
| | Intraoperative Complications | 1 | 2016 | 138 | 0.110 |
Why?
| | Actinomycosis | 1 | 1994 | 4 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 425 | 0.110 |
Why?
| | Nose Diseases | 1 | 1994 | 13 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 220 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 137 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 197 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 385 | 0.110 |
Why?
| | Angiofibroma | 1 | 2013 | 6 | 0.110 |
Why?
| | Pituitary Diseases | 1 | 2013 | 20 | 0.110 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 21 | 0.110 |
Why?
| | Microbiota | 3 | 2018 | 762 | 0.110 |
Why?
| | Case-Control Studies | 5 | 2017 | 3556 | 0.100 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 6 | 0.100 |
Why?
| | Granulocytes | 1 | 2013 | 80 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 1994 | 125 | 0.100 |
Why?
| | Biopsy | 3 | 2017 | 1129 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 43 | 0.100 |
Why?
| | Biofilms | 1 | 2015 | 260 | 0.100 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 51 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 480 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.100 |
Why?
| | Vital Capacity | 1 | 2013 | 311 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.100 |
Why?
| | Skull Neoplasms | 1 | 2012 | 23 | 0.090 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 118 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 301 | 0.090 |
Why?
| | Histocytochemistry | 1 | 2011 | 80 | 0.090 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 62 | 0.090 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 152 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 148 | 0.090 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 329 | 0.090 |
Why?
| | Incidence | 2 | 2015 | 2804 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 1079 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 139 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 402 | 0.080 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.080 |
Why?
| | Caspase 8 | 1 | 2009 | 48 | 0.080 |
Why?
| | Epistaxis | 3 | 2011 | 12 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3566 | 0.080 |
Why?
| | Caspase 9 | 1 | 2009 | 57 | 0.080 |
Why?
| | Bacteria | 1 | 2016 | 858 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2009 | 189 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 73 | 0.070 |
Why?
| | Drug Tolerance | 1 | 2009 | 105 | 0.070 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 18 | 0.070 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 43 | 0.070 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 23 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 852 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1226 | 0.070 |
Why?
| | Maxilla | 1 | 2007 | 38 | 0.070 |
Why?
| | Child | 9 | 2016 | 21935 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 67 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 306 | 0.070 |
Why?
| | Child, Preschool | 5 | 2011 | 11074 | 0.060 |
Why?
| | Reference Values | 1 | 2008 | 816 | 0.060 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 28 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 486 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 431 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1809 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2757 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 849 | 0.060 |
Why?
| | Risk Assessment | 2 | 2013 | 3457 | 0.050 |
Why?
| | Asthma | 2 | 2016 | 2295 | 0.050 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 16 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 2836 | 0.050 |
Why?
| | Fungi | 1 | 2005 | 144 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 186 | 0.050 |
Why?
| | Mouth Diseases | 1 | 2003 | 45 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 3958 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 361 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1120 | 0.050 |
Why?
| | Acute Disease | 2 | 2016 | 1007 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 136 | 0.050 |
Why?
| | United States | 3 | 2015 | 14841 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 169 | 0.050 |
Why?
| | Head | 1 | 2003 | 105 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 522 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2031 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2003 | 202 | 0.040 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 28 | 0.040 |
Why?
| | Ecchymosis | 1 | 2000 | 4 | 0.040 |
Why?
| | Mitomycin | 1 | 2020 | 34 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 342 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 110 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 179 | 0.040 |
Why?
| | Orbital Diseases | 1 | 2000 | 32 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1916 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 450 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 35 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 82 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 91 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 5079 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 5 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 9 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 39 | 0.040 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2000 | 250 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 21 | 0.040 |
Why?
| | Larynx | 1 | 1998 | 60 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 160 | 0.030 |
Why?
| | Skin Tests | 1 | 2018 | 101 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2017 | 38 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 97 | 0.030 |
Why?
| | Probiotics | 1 | 2018 | 54 | 0.030 |
Why?
| | Plasma Cells | 1 | 2017 | 71 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5778 | 0.030 |
Why?
| | Mucus | 1 | 2017 | 79 | 0.030 |
Why?
| | Complementary Therapies | 1 | 2018 | 88 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2828 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 241 | 0.030 |
Why?
| | Carcinoma | 1 | 1998 | 240 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 56 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 510 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 211 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 191 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 289 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1215 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 156 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 56 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 2 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 228 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 3 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 4 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 722 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 13 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 22 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 16 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 67 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 14 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 32 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 85 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 48 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 321 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 50 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 190 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 60 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 230 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 133 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1066 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 86 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 5472 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 90 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 321 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 409 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 216 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 47 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 343 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 565 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 767 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 350 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 136 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 7 | 0.030 |
Why?
| | Perioperative Care | 1 | 2015 | 178 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 549 | 0.030 |
Why?
| | Facial Nerve | 1 | 1993 | 38 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3284 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1289 | 0.030 |
Why?
| | Phospholipase C beta | 1 | 2013 | 29 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 257 | 0.030 |
Why?
| | Transducin | 1 | 2013 | 42 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2017 | 893 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 579 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 169 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 63 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2013 | 329 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 207 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2013 | 109 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1502 | 0.020 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 225 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 307 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10388 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 313 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 686 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 184 | 0.020 |
Why?
| | Hematoma | 1 | 2011 | 53 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 101 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 75 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 220 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 332 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 151 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 673 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 512 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1972 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1325 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1236 | 0.020 |
Why?
| | Animals | 1 | 2012 | 36940 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 429 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1062 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1774 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2085 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1178 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1389 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 820 | 0.020 |
Why?
| | Workload | 1 | 2011 | 167 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 219 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 496 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2074 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 351 | 0.020 |
Why?
| | Pain | 1 | 2013 | 756 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1167 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4149 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1050 | 0.020 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 1993 | 855 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1313 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1043 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4060 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 261 | 0.010 |
Why?
| | Clinical Competence | 1 | 2011 | 1118 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5742 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 12 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 635 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 18 | 0.010 |
Why?
| | Masks | 1 | 2001 | 63 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 27 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 152 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 116 | 0.010 |
Why?
| | Headache | 1 | 2001 | 147 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 19 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1946 | 0.010 |
Why?
| | Infant | 1 | 2011 | 9465 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 344 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1704 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|